Source Cited 1 time

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

U.S. Food and Drug Administration · December 2023

FDA approval of Casgevy (the first CRISPR-based therapy) and Lyfgenia for sickle cell disease.

Cited by 1